From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)
BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) has reinvented itself in a way...
Clinical Trial
Red Light Holland Secures Second United States Controlled Substances Import Permit for the Company’s Psilocybin Through FDA-Compliant, DEA-Registered Partner Irvine Labs
Red Light Holland granted Second DEA Import Permit through Irvine Labs for expanded psilocybin research programThis United States Controlled Substances...
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the...
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced...
CLn Skin Care Appoints Dr. Amir Moradi to Medical Advisory Board
Acclaimed Facial Plastic Surgeon and Educator Joins CLn Skin Care DALLAS, TEXAS / ACCESS Newswire / October 14, 2025 /...
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to...
Every Word Matters: The Next Chapter of Our Universal Patient Language
Originally published on BMS.com in recognition of Health Literacy Month, the following article highlights how Bristol Myers Squibb's Universal Patient...
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed...
Zomedica Expands Grovet’s Distribution Agreement to Include Zomedica’s Diagnostic and Therapeutic Device Products Across the European Union
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in...
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation...
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001)100% of patients were off all topical IOP-lowering medications at...
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to...
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC...
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving...
Halda Therapeutics Announces Oral Plenary Presentation on HLD-0915 Clinical Data in Metastatic Castration-Resistant Prostate Cancer (mCRPC) at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025
Plenary Presentation to be Followed by Poster Presentation Highlighting HLD-0915 Clinical DataBOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics...
Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program
FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two...
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical...
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated...